Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fananserin SCHEMBL5779774 | 1.00 | HTR7 (1.00) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757519 | 0.90 | HTR7 (0.95) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757266 | 0.89 | HTR7 (0.81) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757451 | 0.89 | HTR7 (0.92) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757255 | 0.89 | HTR7 (0.80) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757611 | 0.89 | HTR7 (0.80) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757313 | 0.89 | HTR7 (0.80) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757186 | 0.89 | HTR7 (0.80) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757246 | 0.87 | HTR7 (0.82) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9757364 | 0.86 | HTR7 (0.92) | HTR7HTR1ADRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | claimed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | claimed |
| JP-2002542287-A | — | — | 2002-12-10 | — | — | JP | claimed |
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | SKOGVALL STAFFAN (SE) | 2002-11-21 | — | — | US | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | claimed |
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| US-6100256-A | ORALLY ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT NK-1(NEUROKININ-1, SUBSTANCE P) RECEPTOR ANTAGONIST; FOR PATIENT WHO IS NON-RESPONSIVE TO, OR FOR WHOM ANTIPSYCHOTIC AGENTS ARE CONTRAINDICATED | MERCK SHARP & DOHME LTD. (GB) | 2000-08-08 | — | — | US | claimed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| EP-0350403-B1 | (AZA)NAPHTHALENESULTAM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND DRUGS CONTAINING SAME | RHONE-POULENC SANTE (FR) | 1993-01-13 | — | — | EP | claimed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR7 12/4885HTR1A 3/4885DRD2 51/4885 |
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | HTR4, HTR2C, HTR5A | HTR7 9/4885HTR1A 4/4885DRD2 55/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR7 18/4885HTR1A 38/4885DRD2 106/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR7 6/4885HTR1A 1/4885DRD2 58/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR7 12/4885HTR1A 4/4885DRD2 345/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR7 11/4885HTR1A 3/4885DRD2 45/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | HTR7 11/4885HTR1A 3/4885DRD2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.